Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 25, 2022

Primary Completion Date

June 12, 2023

Study Completion Date

June 12, 2023

Conditions
Submental Fat
Interventions
DRUG

RZL-012

50mg/ml drug formulation

DRUG

RZL-012+Lidacaine injection prior treatment

5ml lidocaine will be injected 10 minutes before RZL-012 treatment

DRUG

RZL-012+Medrol

oral Medrol dose pack (8 mg (2 tablets) on Day 1 before treatment followed by 16 mg after treatment (as per Instructions for Use)). From Day 2, a daily tapering off by 4 mg until Day 6 will be administered per Rx Instructions for use

DRUG

RZL-012+Celecoxib+Zyrtec

200 mg Celecoxib BID and 10 mg Zyrtec BID on Days 1, 2, 3, 4, 5 and 6

DRUG

RZL-012+facial and neck wrap

Universal Facial Band

Trial Locations (1)

10021

Luxurgery, Manhattan

All Listed Sponsors
lead

Raziel Therapeutics Ltd.

INDUSTRY